Juan P. Alderuccio
@JuanAlderuccio
Followers
692
Following
1K
Statuses
387
Hematologist-Oncologist | Lymphoma Physician @SylvesterCancer | @umiamimedicine I Member @ASH_hematology Committee on Educational Affairs & Media Experts
Miami, FL
Joined September 2020
Published in @BloodJournal today, our approach to secondary CNS involvement by aggressive lymphomas Here is a free access link
9
28
108
Out in @CancerNetwrk a report of the @lymphoma 2024 MZL Scientific Workshop including recent advances in biology, biomarkers, drug development, and more
0
3
18
RT @llmcongress: Join us at the LL&M Winter Symposium, February 7-9, 2025, in Miami Beach, featuring @drsangeetmd. She's an assistant profe…
0
7
0
RT @icmlugano: ⌛ Only one month left to take advantage of the #18ICML early registration fee (February 28)! More information: https://t.co…
0
6
0
RT @JillLykon: Hi PGY2 Heme Onc Pharmacy Residents - looking for inpatient hematology clin pharm job after graduation!? UM has a new positi…
0
6
0
RT @majorajay: Great summary table of all studies of CAR-T in CNS lymphomas (primary & secondary). #lymsm #tcellrx
0
16
0
RT @DrRaulCordoba: 🚨🚨🚨 HOT OFF THE PRESS!! #Hematology Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results…
0
17
0
@nico30f Always difficult to select therapy based on retrospective data but I would stick to BR in frontline and those options at relapse. Bispecifics may have higher AEs in these patients as we see with antiCD20 antibodies.
0
0
2
RT @ASH_hematology: ASH is honored to welcome Dr. Belinda Avalos @b_avalos_MD to the role of 2025 ASH President! Dr. Avalos has served AS…
0
7
0
Celebrating with part of our amazing lymphoma research team a productive 2024 with more than 160 patients enrolled in clinical trials @SylvesterCancer @CraigMoskMD
0
1
15
RT @DrAEvens: 👏👏 Entering its 70th year anniversary, please see the inaugural #editorial that will kick off the January 2025 print publicat…
0
8
0
RT @VJHemOnc: At #ASH24, @JuanAlderuccio of @SylvesterCancer presented the results of a Phase II trial investigating loncastuximab tesirine…
0
2
0
RT @TargetedOnc: An Overview of the Current Treatment Landscape for R/R FL With @JuanAlderuccio of @SylvesterCancer
0
2
0
0
4
0
RT @freemanlciaraMD: Excited to share our latest work in @BloodJournal! 📢 We demonstrate how soluble BCMA (sBCMA) quantification and MTV fr…
0
18
0
RT @ComeBommier: Now in @BloodAdvances 🎉 ! 2 key messages: •The cumulative incidence of transformation in #MZL is 5% at 5 years and 8% at…
0
6
0
Our phase Ib trial on secondary CNS lymphoma will start enrollment very soon. Looking forward to collaborating with brilliant colleagues and improving outcomes @AshishHShah4 @TaylorJ_MD @ForesightDx @BeiGeneGlobal @SylvesterCancer
1
6
22
RT @CwynKate: The genomic & clinical consequences of replacing procarbazine with dacarbazine in esc BEACOPP for Hodgkin Lymphoma: retrospec…
0
12
0